Francis Bacon, De Augmentis Scientarum (1605)
Vertebral augmentation has come under intense scrutiny over the last year, following the publication of highly publicized trials and numerous editorials focused on the efficacy of percutaneous vertebroplasty (PV) and kyphoplasty (KP) for relief of pain due to vertebral compression fractures (VCFs). 2, 5, [10] [11] [12] 14, 19, [24] [25] [26] 33, 35, 36 The lay press has concentrated almost solely 21, 32 on two randomized controlled trials (RCTs) published simultaneously in August 2009 in the New England Journal of Medicine (NEJM) that found no difference between PV and a sham anesthetic injection for pain relief in patients with osteoporotic VCFs. 11, 24 Despite this narrow emphasis and the negative impact it has had on the utilization of these procedures, 27 there are, in fact, a number of other RCTs with high levels of evidence that address this very question with far more complex results than these two trials suggest. 17, 26, 33, 35 In this month's issue, Farrhoki et al. 17 add further data to the conflicted evidence base for PV and KP. The authors' primary aim was to compare short-and longterm effects of PV on pain and quality of life (QOL), with secondary assessment of the incidence of new VCFs over 2 years as well as vertebral height and sagittal deformity correction. They did so by performing an RCT comparing PV to optimal medical therapy (OMT) in patients with osteoporotic VCFs. Inclusion criteria required confirmation of symptomatic VCF by physical examination findings of tenderness over the suspected site, in addition to positive x-ray and MR imaging findings. In this singlecenter study, 82 patients were randomized (40 to the PV and 42 to the OMT group) and followed up for 3 years. Statistically and clinically significant dominance for all primary and secondary outcome measures was found in favor of PV at all time points for at least 1 year and up to 3 years on some measures. The incidence of new VCFs was significantly higher in the OMT group than in the PV group. Limitations of the study include its single-center nature, the open-label design, unclear blinding of assessors, and the surprising extent of deformity correction documented post-PV. The authors should be acknowledged for a well-performed trial.
How Did We Get Here?
The state of the evidence base on vertebral augmentation prior to 2009 was perhaps best summarized by meta-analyses on PV and KP performed by Eck et al. 16 in 2008 and on KP performed by Bouza et al. 8 in 2006 . Although the studies included in these analyses often provided low levels of evidence, an overall experience of more than 9000 patients with more than 15,000 fractures from dozens of different centers was summarized. Ultimately, both PV and KP demonstrated a consistent and immediate reduction in VAS pain scores of approximately 5 points. This well-recognized treatment effect is eerily consistent in the majority of RCTs that followed these reviews 17, 26, 33, 35 (and anecdotally identical in our own clinical practice as well).
In March 2009, the "FREE" study reported the results of an RCT comparing the effect of KP on osteoporotic and pathological VCFs versus nonoperative care.
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This multicenter, multinational, industry-sponsored trial enrolled 300 patients over 2 years, with more than 40% of eligible patients agreeing to participate. Inclusion was based primarily on MR imaging findings and clinical judgment, and the outcome measures included QOL, back function and mobility, back pain, narcotic analgesic use, and number of restricted activity days. Kyphoplasty proved superior to nonoperative care for all primary and secondary outcome measures between 6 and 12 months of follow-up. The groups appeared to have similar outcomes by the 12-month point. The VAS back pain scores improved immediately after KP by greater than 4 points. There was no difference in the overall frequency of adverse events or subsequent fractures between groups. Despite being the largest of all the RCTs performed, this study has been largely overlooked by both the lay press and those arguing about the RCTs for PV.
Editorial
See the corresponding article in this issue, pp 561-569.
In August 2009, the sham-controlled trials by Buchbinder et al. 11 and Kallmes et al. 24 produced an entirely different set of results than those seen previously (or since). Critics have rightly pointed out deficiencies that might threaten the validity of the studies. 2, 5, 14, 17, 19, 26, 36 These concerns include the following: 1) difficulties in enrollment that resulted in a greater than 4-year enrollment period for 78 11 and 131 24 participants as well as a broadening of inclusion criteria and reduction in target study size after the study's initiation; 2) the inclusion criteria did not use concordant physical examination findings, but relied primarily on radiographic assessment, which leads to the question of whether many of the treated fractures were actually asymptomatic; 3) the studies included both acute and chronic fractures; 4) a considerable number of patients on chronic narcotic pain medications were enrolled in both trials, possibly diluting any treatment effect; 5) the multicenter nature of the study by Buchbinder et al. has been challenged, since 68% of all procedures were performed at a single institution by one radiologist; 11,14 6) the procedures and evaluations were performed only by radiologists rather than clinically oriented spine specialists; 7) only unilateral approaches with small cement volumes were used during PV; 8) material used in the sham procedure in Kallmes et al. 24 was not inert, and may have acted as a facet or periosteal block, with a therapeutic effect; 9) there was a high crossover ratio in Kallmes et al. 24 (33% assigned to sham and 12% assigned to PV) that ultimately decreased the power to detect significant effect differences; and 10) most notably, neither the PV nor the sham groups enjoyed the magnitude of pain reduction seen in nearly all prior and subsequent PV/KP studies. Specifically, Buchbinder et al. found only an approximately 2-point VAS reduction in both groups at 1 week and at 1, 3, and 6 months, and Kallmes et al. found only an approximately 3-point VAS reduction in both groups at 3 days, 2 weeks, and 1 month. This overall diminution of a well-established treatment effect was never adequately explained by either set of authors. In fact, rather than reducing the effect, one would expect a placebo to have reproduced or even heightened the effect.
Farrokhi et al. 17 point out the differences between their current study and those of Kallmes et al. 24 and Buchbinder et al. 11 Despite enrolling patients at just a single center, they were able to collect their desired study population in only 15 months, whereas the other studies required 4 years to enroll approximately the same number. Only 2% of eligible patients in Farrokhi et al. declined enrollment, versus 64%-70% in the sham-controlled trials.
11,24 The inclusion criteria in Farrokhi et al. stipulated the need for physical examination evidence of tenderness over the putative fracture site concordant with x-ray and MR imaging findings (a routine practice pattern missing in the NEJM studies 11, 24 ). The timing of enrollment after fracture onset (4 weeks to 1 year) was similar, but "painless" VCFs were excluded, thus avoiding patients with nonspecific chronic back pain that probably contaminated the sham-controlled trials' populations and who may have actually had a treatment response to the anesthetic sham injection. Response to PV included an immediate 5-point reduction in VAS scores not seen in the control group or in either group in the sham-controlled studies.
In 2010, two additional RCTs comparing PV to nonoperative treatment have been published. 26, 33 Rousing et al. 33 randomized 50 patients with acute osteoporotic VCFs at a single center in Denmark over the course of 7 years and found no difference in pain scores between groups at 3 and 12 months. However, the PV group showed a 6-point reduction in VAS within 24 hours of treatment, which was not seen in the control group. This difference was sustained at the 1-month follow-up point, but was lost after 3 months. This effect reduction may relate to the natural history of the disease, but may also signal lack of power in the study to detect differences over time, possibly exacerbated by the fact that the PV group had a statistically significantly lower baseline VAS score than the control group prior to enrollment.
Klazen et al. 26 have published results of the Vertos II study examining PV versus nonoperative care in 202 randomized patients with acute osteoporotic VCFs at multiple centers over 3 years. Inclusion required concordance of physical examination findings and radiographic findings of acute VCF. This study provides an interesting view into the natural history of acute fractures; 50% of screened patients were ultimately deemed ineligible because their fracture pain resolved in the time period between initial screening and enrollment. The process of procuring participants in this study may, in fact, have screened out many of the patients with severe pain who ultimately "regress to the mean," a phenomenon that some claim overestimates the treatment effects typically seen in PV/KP studies. The authors report a greater than 4-point immediate reduction in VAS scores in the PV group not seen in the controls. Clinically and statistically significant differences in pain levels were found in favor of PV over control for 12 months postenrollment.
How Do We Put the Evidence Base Into Practice?
Given that surgical RCTs are extremely difficult to perform, one may be willing to concede certain flaws in the internal validity of these studies. However, in generating practice recommendations one simply cannot ignore the serious threats to external validity. The process of extrapolating clinical research data to clinical practice relies on a critical evaluation of the generalizability of the results presented. 6, 18, 22, 30, 31, 34 Despite their status as the gold standard of clinical research, RCTs are often a form of "test tube" medicine. The restrictions and circumstances present in the study protocol and participating institutions rarely match the heterogeneity and characteristics of "real-life" practice. 1, 18, 34 Generalizing results from RCTs requires a deep understanding of the tightly controlled conditions of the trial and the often unique characteristics of the patients enrolled. The results of single-center trials such as that of Farrokhi et al. 17 (and in essence Buchbinder et al.
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) must be applied with caution because they may not be reproducible elsewhere.
3,34 On the other hand, the high ratio of eligible to enrolled patients in Farrokhi et al. circumvents the "exclusion bias" seen in the NEJM studies 11, 24 that threatened their external validity and, in fact, makes the current study resonate as more "real-world." Multi-
